Lebrikizumab + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atopic Hand and Foot Dermatitis
Conditions
Atopic Hand and Foot Dermatitis
Trial Timeline
Apr 21, 2025 → Sep 1, 2026
NCT ID
NCT06921759About Lebrikizumab + Placebo
Lebrikizumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Atopic Hand and Foot Dermatitis. The current trial status is active. This product is registered under clinical trial identifier NCT06921759. Target conditions include Atopic Hand and Foot Dermatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06921759 | Phase 3 | Active |
| NCT06243198 | Phase 1 | Completed |
| NCT05735483 | Phase 3 | Recruiting |
| NCT04626297 | Phase 3 | Completed |
| NCT03443024 | Phase 2 | Completed |
Competing Products
20 competing products in Atopic Hand and Foot Dermatitis